Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation
JAMA · 2023
DOI: 10.1001/jama.2023.3079 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von S Sean Tu und 4 weiteren Autor:innen. Beteiligte Einrichtung: West Virginia University College of Law, Morgantown. Hauptthemen laut MEDLINE: Commerce, Orphan Drug Production, Prescription Drugs. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This study evaluates sales revenue earned in the first 5 years for newly marketed brand-name drugs with and without an initial orphan drug designation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- West Virginia University College of Law, Morgantown.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
Zitieren
APA
Tu, S. S., Nagar, S., Kesselheim, A. S., Lu, Z., & Rome, B. N. (2023). Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation. JAMA. https://doi.org/10.1001/jama.2023.3079
Vancouver
Tu SS, Nagar S, Kesselheim AS, Lu Z, Rome BN. Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation. JAMA. 2023. doi:10.1001/jama.2023.3079
BibTeX
@article{Tu2023,
author = {Tu, S Sean and Nagar, Sarosh and Kesselheim, Aaron S and Lu, Zhigang and Rome, Benjamin N},
title = {Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.3079}
}
EUVIMED